Pulse Biosciences (NASDAQ:PLSE) Now Covered by Oppenheimer

Oppenheimer initiated coverage on shares of Pulse Biosciences (NASDAQ:PLSE - Free Report) in a report released on Monday morning, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $22.00 price objective on the stock.

Separately, Wall Street Zen raised shares of Pulse Biosciences to a "sell" rating in a research note on Monday, March 31st.

Pulse Biosciences Stock Performance

Shares of NASDAQ:PLSE traded up $0.93 on Monday, reaching $17.12. The company's stock had a trading volume of 144,526 shares, compared to its average volume of 178,170. Pulse Biosciences has a 52-week low of $13.50 and a 52-week high of $25.00. The company has a 50-day simple moving average of $16.34 and a 200 day simple moving average of $17.48.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.25) EPS for the quarter.

Insider Activity

In other news, CTO Darrin Uecker sold 15,000 shares of the firm's stock in a transaction dated Thursday, June 12th. The shares were sold at an average price of $16.40, for a total value of $246,000.00. Following the completion of the sale, the chief technology officer owned 137,872 shares in the company, valued at approximately $2,261,100.80. This trade represents a 9.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 71.50% of the company's stock.

Institutional Investors Weigh In On Pulse Biosciences

Institutional investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC lifted its holdings in shares of Pulse Biosciences by 98.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,692 shares of the company's stock worth $29,000 after acquiring an additional 838 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of Pulse Biosciences in the 4th quarter worth about $44,000. AlphaQuest LLC lifted its holdings in Pulse Biosciences by 68.0% during the 1st quarter. AlphaQuest LLC now owns 3,116 shares of the company's stock valued at $50,000 after buying an additional 1,261 shares in the last quarter. Caisse Des Depots ET Consignations bought a new stake in Pulse Biosciences during the 4th quarter valued at about $95,000. Finally, PNC Financial Services Group Inc. bought a new stake in Pulse Biosciences during the 1st quarter valued at about $90,000. Institutional investors own 76.95% of the company's stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.